IMPAACT 2010 is a Phase III, three-arm, randomized, open-label study of HIV-1-infected pregnant women initiating either a...
Rationale: There is an urgent need for a platform to rapidly evaluate therapies in the outpatient setting, to prevent disease...
A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...
Study Objective: Compare longitudinal HIV-1 antibody responses among HIV-1 infected participants that either did or did not...
1077FF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...
